Quote | Cabaletta Bio Inc. (NYSE:CABA)
Last: | $ |
---|---|
Change Percent: | -1.04% |
Open: | $15.50 |
Close: | $15.26 |
High: | $15.79 |
Low: | $14.94 |
Volume: | 23,636 |
Last Trade Date Time: | 02/12/2020 04:43:39 pm |
News | Cabaletta Bio Inc. (NYSE:CABA)
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-28 13:42:28 ET Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarka...
Message Board Posts | Cabaletta Bio Inc. (NYSE:CABA)
Subject | By | Source | When |
---|---|---|---|
$CABA MomentumIts now last up | crudeoil24 | investorshub | 05/13/2023 2:40:36 AM |
$CABA news out | Diggie-HH | investorshub | 04/25/2023 11:48:41 AM |
MomentumIts trading last up | TheFinalCD | investorshub | 04/21/2023 1:02:49 AM |
$CABA just the news we needed | crudeoil24 | investorshub | 04/20/2023 12:26:59 PM |
Great call! | Alan Brown | investorshub | 01/30/2023 12:49:45 PM |
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...